Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2025-07-28

Verve Therapeutics (VERV)

CEO Sekar Kathiresan was paid $7,442,663 in fiscal year 2024 (SEC filing 0000950170-25-058325 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$7,442,663
Sekar Kathiresan total, FY2024
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
95.33%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Sekar Kathiresan (Chief Executive Officer), FY2024 total compensation $7,442,663 (base salary $639,231) [exec_comp, SEC accession 0000950170-25-058325, filed 2025-04-25]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Sekar Kathiresan$639,231$0$1,683,000$4,727,372$378,972$0$14,088$7,442,663
Chief Executive Officer
Andrew Bellinger243,8460573,7502,038,94600574,3583,430,900
Former Chief Scientific Officer
Allison Dorval469,4230573,7501,617,732206,712014,0882,881,705
Chief Financial Officer
Andrew Ashe389,0770459,0001,348,110172,260011,6182,380,065
President, Chief Operating Officer and General Counsel

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Sekar Kathiresan$7,442,663—$7,846,718—
Andrew Bellinger3,430,900—3,319,498—
Allison Dorval2,881,705———
Andrew Ashe2,380,065—3,319,498—

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Verve Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper VERV reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against VERV
10 companies name VERV as a compensation peer

Each company listed discloses VERV in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VERV in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2024 total
Andrew AshePresident$2,380,065
Andrew BellingerChief Scientific Officer$3,430,900
Allison DorvalCFO$2,881,705
Sekar KathiresanCEO$7,442,663
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Alexander CumboIndependent Director$521,499
Burt Adelman, M.DChair of the Board$568,999
Jodie MorrisonIndependent Director$964,970
Krishna Yeshwant, M.DIndependent Director$522,667
Lonnel CoatsIndependent Director$521,499
Michael MacLeanIndependent Director$533,999
Ourania Tatsis, Ph.DDirector—
Sheila Mikhail, J.DIndependent Director$526,499
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Krishna YeshwantDirector2025-06-05A42,200$0$0Derivative, Class A CommonForm 4 ↗
Alexander CumboDirector2025-06-05A42,20000Derivative, Class A CommonForm 4 ↗
Ourania TatsisDirector2025-06-05A42,20000Derivative, Class A CommonForm 4 ↗
Burt A. AdelmanDirector2025-06-05A42,20000Derivative, Class A CommonForm 4 ↗
Sheila MikhailDirector2025-06-05A42,20000Derivative, Class A CommonForm 4 ↗
Jodie MorrisonDirector2025-06-05A42,20000Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-06-05A42,20000Derivative, Class A CommonForm 4 ↗
Michael MacLeanDirector2025-06-05A42,20000Derivative, Class A CommonForm 4 ↗
Jason PolitiChief Technical Ops. Off.2025-07-25D90,000——Derivative, Class A CommonForm 4 ↗
Jason PolitiChief Technical Ops. Off.2025-07-25D16,405——CommonForm 4 ↗
Andrew AsheSee Remarks2025-07-25D150,000——Derivative, Class A CommonForm 4 ↗
Andrew AsheSee Remarks2025-07-25D40,000——Derivative, Class A CommonForm 4 ↗
Andrew AsheSee Remarks2025-07-25D225,000——Derivative, Class A CommonForm 4 ↗
Andrew AsheSee Remarks2025-07-25D348,828——CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D75,105——Derivative, Class A CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D138,995——Derivative, Class A CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D240,997——CommonForm 4 ↗
Joan NickersonChief Administrative Officer2025-07-25D225,000——Derivative, Class A CommonForm 4 ↗
Allison DorvalChief Financial Officer2025-07-25D13,280——CommonForm 4 ↗
Andrew AsheSee Remarks2025-07-25D27,000——Derivative, Class A CommonForm 4 ↗
Jason PolitiChief Technical Ops. Off.2025-07-25D225,000——Derivative, Class A CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D167,425——Derivative, Class A CommonForm 4 ↗
Ourania TatsisDirector2025-07-25D267,541——Derivative, Class A CommonForm 4 ↗
Jason PolitiChief Technical Ops. Off.2025-07-25D118,796——Derivative, Class A CommonForm 4 ↗
Andrew AsheSee Remarks2025-07-25D26,999——Derivative, Class A CommonForm 4 ↗
Troy ListerChief Scientific Officer2025-07-25D32,000——Derivative, Class A CommonForm 4 ↗
Troy ListerChief Scientific Officer2025-07-25D40,000——Derivative, Class A CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D431,988——Derivative, Class A CommonForm 4 ↗
Joan NickersonChief Administrative Officer2025-07-25D125,000——Derivative, Class A CommonForm 4 ↗
Joan NickersonChief Administrative Officer2025-07-25D6,630——Derivative, Class A CommonForm 4 ↗
Joan NickersonChief Administrative Officer2025-07-25D17,420——CommonForm 4 ↗
Krishna YeshwantDirector2025-07-25D136,139——Derivative, Class A CommonForm 4 ↗
Krishna YeshwantDirector2025-07-25D6,108,442——Common, indirectForm 4 ↗
Michael MacLeanDirector2025-07-25D42,200——Derivative, Class A CommonForm 4 ↗
Alexander CumboDirector2025-07-25D136,139——Derivative, Class A CommonForm 4 ↗
Troy ListerChief Scientific Officer2025-07-25D225,000——Derivative, Class A CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D488,000——Derivative, Class A CommonForm 4 ↗
Jodie MorrisonDirector2025-07-25D42,200——Derivative, Class A CommonForm 4 ↗
Troy ListerChief Scientific Officer2025-07-25D6,952——CommonForm 4 ↗
Alexander CumboDirector2025-07-25D42,200——Derivative, Class A CommonForm 4 ↗
Sheila MikhailDirector2025-07-25D43,198——Derivative, Class A CommonForm 4 ↗
Sheila MikhailDirector2025-07-25D42,200——Derivative, Class A CommonForm 4 ↗
Sheila MikhailDirector2025-07-25D136,139——Derivative, Class A CommonForm 4 ↗
Ourania TatsisDirector2025-07-25D42,200——Derivative, Class A CommonForm 4 ↗
Jason PolitiChief Technical Ops. Off.2025-07-25D25,000——Derivative, Class A CommonForm 4 ↗
Jason PolitiChief Technical Ops. Off.2025-07-25D16,500——Derivative, Class A CommonForm 4 ↗
Jason PolitiChief Technical Ops. Off.2025-07-25D6,630——Derivative, Class A CommonForm 4 ↗
Jason PolitiChief Technical Ops. Off.2025-07-25D40,000——Derivative, Class A CommonForm 4 ↗
Andrew AsheSee Remarks2025-07-25D153,278——Derivative, Class A CommonForm 4 ↗
Burt A. AdelmanDirector2025-07-25D42,200——Derivative, Class A CommonForm 4 ↗
Troy ListerChief Scientific Officer2025-07-25D69,500——Derivative, Class A CommonForm 4 ↗
Troy ListerChief Scientific Officer2025-07-25D6,630——Derivative, Class A CommonForm 4 ↗
Troy ListerChief Scientific Officer2025-07-25D12,075——Derivative, Class A CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D526,000——Derivative, Class A CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D99,000——Derivative, Class A CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D120,000——Derivative, Class A CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D150,000——Derivative, Class A CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D110,997——CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D348,431——CommonForm 4 ↗
Joan NickersonChief Administrative Officer2025-07-25D102,016——Derivative, Class A CommonForm 4 ↗
Joan NickersonChief Administrative Officer2025-07-25D18,000——Derivative, Class A CommonForm 4 ↗
Joan NickersonChief Administrative Officer2025-07-25D40,000——Derivative, Class A CommonForm 4 ↗
Allison DorvalChief Financial Officer2025-07-25D180,000——Derivative, Class A CommonForm 4 ↗
Allison DorvalChief Financial Officer2025-07-25D1,875——Derivative, Class A CommonForm 4 ↗
Allison DorvalChief Financial Officer2025-07-25D33,750——Derivative, Class A CommonForm 4 ↗
Allison DorvalChief Financial Officer2025-07-25D45,000——Derivative, Class A CommonForm 4 ↗
Allison DorvalChief Financial Officer2025-07-25D75,000——Derivative, Class A CommonForm 4 ↗
Krishna YeshwantDirector2025-07-25D42,200——Derivative, Class A CommonForm 4 ↗
Krishna YeshwantDirector2025-07-25D1,800,000——Common, indirectForm 4 ↗
Krishna YeshwantDirector2025-07-25D4,260,047——Common, indirectForm 4 ↗
Michael MacLeanDirector2025-07-25D136,139——Derivative, Class A CommonForm 4 ↗
Burt A. AdelmanDirector2025-07-25D428,326——CommonForm 4 ↗
Sekar KathiresanDirector2025-07-25D500,203——Derivative, Class A CommonForm 4 ↗
Allison DorvalChief Financial Officer2025-07-25D258,000——Derivative, Class A CommonForm 4 ↗
Andrew AsheSee Remarks2025-07-25D107,997——Derivative, Class A CommonForm 4 ↗
Jodie MorrisonDirector2025-07-25D267,541——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-25D42,200——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-25D136,139——Derivative, Class A CommonForm 4 ↗
Burt A. AdelmanDirector2025-07-25D43,198——Derivative, Class A CommonForm 4 ↗
Burt A. AdelmanDirector2025-07-25D136,139——Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Sekar KathiresanPSU—————$1,683,000
Andrew AsheOPTION—————1,348,110
Allison DorvalOPTION—————1,617,732
Andrew AshePSU—————459,000
Andrew BellingerOPTION—————2,038,946
Allison DorvalPSU—————573,750
Andrew BellingerPSU—————573,750
Sekar KathiresanOPTION—————4,727,372
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Sekar Kathiresan$0$1,683,000$4,727,37226.3%
Andrew Ashe0459,0001,348,11025.4%
Allison Dorval0573,7501,617,73226.2%
Andrew Bellinger0573,7502,038,94622.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Allison DorvalRSU1,875—$10,575
Andrew AsheOption99,01521.76—
Andrew AsheOption150,00012.75—
Allison DorvalOption30,94333.25—
Allison DorvalOption17,50030.94—
Andrew AsheOption01.48—
Sekar KathiresanOption01.39—
Sekar KathiresanOption01.48—
Sekar KathiresanOption08.24—
Sekar KathiresanOption019—
Sekar KathiresanOption021.76—
Andrew AsheOption02.87—
Sekar KathiresanOption18,0008.24—
Sekar KathiresanOption6,75019—
Sekar KathiresanOption96,83830.94—
Sekar KathiresanOption298,01421.76—
Sekar KathiresanOption526,00012.75—
Andrew AsheOption4,5008.24—
Andrew AsheOption2,70019—
Andrew AsheOption36,45930.94—
Allison DorvalOption180,00012.75—
Sekar KathiresanOption02.87—
Sekar KathiresanOption034.88—
Sekar KathiresanRSU132,000—744,480
Andrew AsheRSU36,000—203,040
Sekar KathiresanOption030.94—
Allison DorvalRSU45,000—253,800
Allison DorvalOption99,01521.76—
05

Incentive-plan design — the Compensation Discussion & Analysis

equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantRadford Data & Analytics from Aon plc
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-0556,159,1362,748,937478,38195.33%Passed
20242024-06-0639,396,0505,481,52425,64487.79%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-06-0595.33%a
20242024-06-0687.79%b

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on Proposals No.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on Proposals No.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jodie MorrisonIndependent · Compensation · Research and Development · Newly elected$26,971$0$937,999$0$0$964,970
Burt Adelman, M.DIndependent · Board Chair · Compensation (Chair) · Nominating/Governance (Chair)100,0000468,99900568,999
Michael MacLeanIndependent · Audit (Chair)65,0000468,99900533,999
Sheila Mikhail, J.DIndependent · Audit · Nominating/Governance57,5000468,99900526,499
Krishna Yeshwant, M.DIndependent · Nominating/Governance53,6680468,99900522,667
Lonnel CoatsIndependent · Audit52,5000468,99900521,499
Alexander CumboIndependent · Compensation52,5000468,99900521,499
Sekar Kathiresan, M.DEmployee director000—00
Ourania Tatsis, Ph.DNot independent · Research and Development (Chair) · Newly elected—0—00—
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$468,999
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)11,250 / 7,500 / 5,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$408,139
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$408,139

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Verve Therapeutics2024Sekar Kathiresan$639,231$1,683,000$4,727,372$378,972$7,442,663

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Verve Therapeutics in fiscal 2024?
As disclosed, Sekar Kathiresan (Chief Executive Officer) was the highest-paid executive at Verve Therapeutics in fiscal 2024, with total compensation of $7,442,663.
How did shareholders vote on Verve Therapeutics's executive compensation?
As disclosed, 95.33% of shareholders supported Verve Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Verve Therapeutics spend in total on board compensation for fiscal 2024?
As disclosed, Verve Therapeutics reported total board compensation of $408,139 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Sekar KathiresanDEF 14A2025-04-250000950170-25-058325Section “Summary compensation table” · page 17. As printed: 7,442,663. Filing ↗machine: r2 · c20 · span 327433–327442
2Section 01, Andrew BellingerDEF 14A2025-04-250000950170-25-058325Section “Summary compensation table” · page 17. As printed: 3,430,900. Filing ↗machine: r5 · c20 · span 348506–348515
3Section 01, Allison DorvalDEF 14A2025-04-250000950170-25-058325Section “Summary compensation table” · page 17. As printed: 2,881,705. Filing ↗machine: r11 · c20 · span 388418–388427
4Section 01, Andrew AsheDEF 14A2025-04-250000950170-25-058325Section “Summary compensation table” · page 17. As printed: 2,380,065. Filing ↗machine: r8 · c20 · span 369568–369577
5Section 03, Sekar Kathiresan PSUDEF 14A2025-04-250000950170-25-058325Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r2 · c8 · span 323099–323108
6Section 03, Andrew Ashe OPTIONDEF 14A2025-04-250000950170-25-058325Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r8 · c11 · span 366232–366241
7Section 03, Allison Dorval OPTIONDEF 14A2025-04-250000950170-25-058325Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r11 · c11 · span 385082–385091
8Section 03, Andrew Ashe PSUDEF 14A2025-04-250000950170-25-058325Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r8 · c8 · span 365236–365243
9Section 03, Andrew Bellinger OPTIONDEF 14A2025-04-250000950170-25-058325Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r5 · c11 · span 345169–345178
10Section 03, Allison Dorval PSUDEF 14A2025-04-250000950170-25-058325Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r11 · c8 · span 384086–384093
11Section 03, Andrew Bellinger PSUDEF 14A2025-04-250000950170-25-058325Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r5 · c8 · span 344173–344180
12Section 03, Sekar Kathiresan OPTIONDEF 14A2025-04-250000950170-25-058325Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t9 · r2 · c11 · span 324097–324106
13Section 08, Jodie MorrisonDEF 14A2025-04-250000950170-25-058325Section “Director Compensation”. As printed: 964,970. Filing ↗machine: t14 · r7 · c11 · span 764283–764509
14Section 08, Burt Adelman, M.DDEF 14A2025-04-250000950170-25-058325Section “Director Compensation”. As printed: 568,999. Filing ↗machine: t14 · r2 · c11 · span 742085–742311
15Section 08, Michael MacLeanDEF 14A2025-04-250000950170-25-058325Section “Director Compensation”. As printed: 533,999. Filing ↗machine: t14 · r5 · c11 · span 755399–755625
16Section 08, Sheila Mikhail, J.DDEF 14A2025-04-250000950170-25-058325Section “Director Compensation”. As printed: 526,499. Filing ↗machine: t14 · r6 · c11 · span 759844–760070
17Section 08, Krishna Yeshwant, M.DDEF 14A2025-04-250000950170-25-058325Section “Director Compensation”. As printed: 522,667. Filing ↗machine: t14 · r9 · c11 · span 773580–773806
18Section 08, Lonnel CoatsDEF 14A2025-04-250000950170-25-058325Section “Director Compensation”. As printed: 521,499. Filing ↗machine: t14 · r3 · c11 · span 746522–746748
19Section 08, Alexander CumboDEF 14A2025-04-250000950170-25-058325Section “Director Compensation”. As printed: 521,499. Filing ↗machine: t14 · r4 · c11 · span 750962–751188
20Section 08, Sekar Kathiresan, M.DDEF 14A2025-04-250000950170-25-058325Section “Director Compensation”. As printed: 0. Filing ↗
21Section 08, Ourania Tatsis, Ph.DDEF 14A2025-04-250000950170-25-058325Section “Director Compensation”. As printed: —. Filing ↗machine: t14 · r8 · c11 · span 768933–768940
22Section 02, Krishna Yeshwant 2025-06-05Form 42025-06-060000950170-25-083226Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Alexander Cumbo 2025-06-05Form 42025-06-060000950170-25-083234Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Ourania Tatsis 2025-06-05Form 42025-06-060000950170-25-083227Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Burt A. Adelman 2025-06-05Form 42025-06-060000950170-25-083230Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Sheila Mikhail 2025-06-05Form 42025-06-060000950170-25-083231Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Jodie Morrison 2025-06-05Form 42025-06-060000950170-25-083232Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Lonnel Coats 2025-06-05Form 42025-06-060000950170-25-083233Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Michael MacLean 2025-06-05Form 42025-06-060000950170-25-083229Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Jason Politi 2025-07-25Form 42025-07-280000950170-25-099255Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Jason Politi 2025-07-25Form 42025-07-280000950170-25-099255Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Andrew Ashe 2025-07-25Form 42025-07-280000950170-25-099254Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Andrew Ashe 2025-07-25Form 42025-07-280000950170-25-099254Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Andrew Ashe 2025-07-25Form 42025-07-280000950170-25-099254Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Andrew Ashe 2025-07-25Form 42025-07-280000950170-25-099254Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Joan Nickerson 2025-07-25Form 42025-07-280000950170-25-099261Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Allison Dorval 2025-07-25Form 42025-07-280000950170-25-099262Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Andrew Ashe 2025-07-25Form 42025-07-280000950170-25-099254Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Jason Politi 2025-07-25Form 42025-07-280000950170-25-099255Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Ourania Tatsis 2025-07-25Form 42025-07-280000950170-25-099252Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Jason Politi 2025-07-25Form 42025-07-280000950170-25-099255Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Andrew Ashe 2025-07-25Form 42025-07-280000950170-25-099254Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Troy Lister 2025-07-25Form 42025-07-280000950170-25-099259Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Troy Lister 2025-07-25Form 42025-07-280000950170-25-099259Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Joan Nickerson 2025-07-25Form 42025-07-280000950170-25-099261Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Joan Nickerson 2025-07-25Form 42025-07-280000950170-25-099261Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Joan Nickerson 2025-07-25Form 42025-07-280000950170-25-099261Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Krishna Yeshwant 2025-07-25Form 42025-07-280000950170-25-099263Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Krishna Yeshwant 2025-07-25Form 42025-07-280000950170-25-099263Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Michael MacLean 2025-07-25Form 42025-07-280000950170-25-099264Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Alexander Cumbo 2025-07-25Form 42025-07-280000950170-25-099251Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Troy Lister 2025-07-25Form 42025-07-280000950170-25-099259Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Jodie Morrison 2025-07-25Form 42025-07-280000950170-25-099256Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Troy Lister 2025-07-25Form 42025-07-280000950170-25-099259Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Alexander Cumbo 2025-07-25Form 42025-07-280000950170-25-099251Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Sheila Mikhail 2025-07-25Form 42025-07-280000950170-25-099253Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Sheila Mikhail 2025-07-25Form 42025-07-280000950170-25-099253Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Sheila Mikhail 2025-07-25Form 42025-07-280000950170-25-099253Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Ourania Tatsis 2025-07-25Form 42025-07-280000950170-25-099252Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Jason Politi 2025-07-25Form 42025-07-280000950170-25-099255Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Jason Politi 2025-07-25Form 42025-07-280000950170-25-099255Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Jason Politi 2025-07-25Form 42025-07-280000950170-25-099255Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Jason Politi 2025-07-25Form 42025-07-280000950170-25-099255Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Andrew Ashe 2025-07-25Form 42025-07-280000950170-25-099254Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Burt A. Adelman 2025-07-25Form 42025-07-280000950170-25-099258Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Troy Lister 2025-07-25Form 42025-07-280000950170-25-099259Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Troy Lister 2025-07-25Form 42025-07-280000950170-25-099259Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Troy Lister 2025-07-25Form 42025-07-280000950170-25-099259Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Joan Nickerson 2025-07-25Form 42025-07-280000950170-25-099261Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Joan Nickerson 2025-07-25Form 42025-07-280000950170-25-099261Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Joan Nickerson 2025-07-25Form 42025-07-280000950170-25-099261Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Allison Dorval 2025-07-25Form 42025-07-280000950170-25-099262Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Allison Dorval 2025-07-25Form 42025-07-280000950170-25-099262Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Allison Dorval 2025-07-25Form 42025-07-280000950170-25-099262Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Allison Dorval 2025-07-25Form 42025-07-280000950170-25-099262Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Allison Dorval 2025-07-25Form 42025-07-280000950170-25-099262Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Krishna Yeshwant 2025-07-25Form 42025-07-280000950170-25-099263Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Krishna Yeshwant 2025-07-25Form 42025-07-280000950170-25-099263Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Krishna Yeshwant 2025-07-25Form 42025-07-280000950170-25-099263Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Michael MacLean 2025-07-25Form 42025-07-280000950170-25-099264Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Burt A. Adelman 2025-07-25Form 42025-07-280000950170-25-099258Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Sekar Kathiresan 2025-07-25Form 42025-07-280000950170-25-099260Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Allison Dorval 2025-07-25Form 42025-07-280000950170-25-099262Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Andrew Ashe 2025-07-25Form 42025-07-280000950170-25-099254Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Jodie Morrison 2025-07-25Form 42025-07-280000950170-25-099256Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Lonnel Coats 2025-07-25Form 42025-07-280000950170-25-099257Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Lonnel Coats 2025-07-25Form 42025-07-280000950170-25-099257Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Burt A. Adelman 2025-07-25Form 42025-07-280000950170-25-099258Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Burt A. Adelman 2025-07-25Form 42025-07-280000950170-25-099258Insider equity transaction reported since the proxy statement. Filing ↗
102Section 06, 2025 voteForm 8-K2025-06-100001193125-25-138470Item 5.07 · say-on-pay result. As reported: 95.33% (votes for as printed: 56,159,136). Filing ↗
103Section 06, 2024 voteForm 8-K2024-06-070001193125-24-157327Item 5.07 · say-on-pay result. As reported: 87.79% (votes for as printed: 39,396,050). Filing ↗
104Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
105Section 09b board cost (computed)Computed——Cash 408,139 + equity 0 + all other 0 = 408,139, summed across the director compensation table rows.machine: formula: Σ = 408,139
106Verve Therapeutics (subject), Section 10b CEO totalDEF 14A2025-04-250000950170-25-058325CEO total compensation as printed in Verve Therapeutics's own proxy. As printed: 7,442,663. Filing ↗machine: r2 · c20 · span 327433–327442

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.